Carr Brian I, Ince Volkan, Bag Harika Gozukara, Ersan Veysel, Usta Sertac, Yilmaz Sezai
Deptment of Surgery, Liver Transplantation Institute, Inonu University, Turkey.
Deptment of Biostatistics, Medical School, Inonu University, Turkey.
Clin Pract (Lond). 2020;17(3):1497-1505.
A characteristic of Hepatocellular Carcinoma (HCC) is to invade the portal venous system in the liver as a means of spread within the liver and systemically. The ensuing Portal Vein Thrombosis (PVT) is a poor prognosis parameter and often diagnosed radiologically pre-treatment. More limited Microvascular Portal Invasion (microPVI) is typically diagnosed on examination of tumors removed after treatment by resection or transplant. The biological characteristics and subsets of PVI are incompletely characterized.
To examine HCC patients with and without microPVI to understand the clinical relationships to other tumor and clinical characteristics and to survival.
A cohort of 270 liver transplant patients with HCC without macroscopic PVT that were available to us was examined. Patients with (165) and without (105) microPVI were compared for survival and clinical features.
The mean survival of patients with and without microPVI was significantly different: 86.6 versus 110.5 months, p=0.007.The microPVI+ patients differed from microPVI- patients in having a significantly larger number of tumor nodules, tumor size and higher serum levels of both Alpha-Fetoprotein (AFP) and almost significant for higher Gamma-Glutamyl Transpeptidase (GGT, p=0.053). Survival in microPVI+ patients related significantly to serum GGT (p=0.006) but not to AFP levels. The incidence of microPVI increased with increase in tumor size and survival decreased significantly with increase in tumor size for microPVI patients. Increase in tumor size was also associated with significantly higher serum GGT levels in patients who were microPVI+, but not in those who were microPVI. Furthermore, patients with microPVI who had prolonged survival significantly differed from those with shorter survival in respect only to tumor size and serum GGT levels.
These findings draw attention to a group of patients with microPVI who have long survival and to the usefulness of serum GGT levels in their evaluation and prognosis.
肝细胞癌(HCC)的一个特征是侵犯肝脏的门静脉系统,作为在肝脏内和全身扩散的一种方式。随之而来的门静脉血栓形成(PVT)是一个预后不良的参数,通常在治疗前通过影像学诊断。更局限的微血管门静脉侵犯(microPVI)通常在对经切除或移植治疗后切除的肿瘤进行检查时诊断出来。PVI的生物学特征和亚组尚未完全明确。
研究有和无微血管门静脉侵犯(microPVI)的肝癌患者,以了解其与其他肿瘤及临床特征和生存的临床关系。
对我们可获得的270例无宏观门静脉血栓形成(PVT)的肝癌肝移植患者队列进行研究。比较有(165例)和无微血管门静脉侵犯(microPVI,105例)患者的生存情况和临床特征。
有和无微血管门静脉侵犯(microPVI)患者的平均生存期有显著差异:分别为86.6个月和110.5个月,p = 0.007。有微血管门静脉侵犯(microPVI)的患者与无微血管门静脉侵犯(microPVI)的患者不同,前者的肿瘤结节数量显著更多、肿瘤更大,血清甲胎蛋白(AFP)水平更高,且血清γ-谷氨酰转肽酶(GGT)水平几乎显著更高(p = 0.05)。有微血管门静脉侵犯(microPVI)患者的生存与血清GGT显著相关(p = 0.006),但与AFP水平无关。微血管门静脉侵犯(microPVI)的发生率随肿瘤大小增加而升高,对于有微血管门静脉侵犯(microPVI)的患者,生存期随肿瘤大小增加而显著缩短。肿瘤大小增加还与有微血管门静脉侵犯(microPVI)患者的血清GGT水平显著升高相关,但与无微血管门静脉侵犯(microPVI)患者无关。此外,生存期延长的有微血管门静脉侵犯(microPVI)患者与生存期较短的患者仅在肿瘤大小和血清GGT水平方面存在显著差异。
这些发现使人们关注到一组生存期长的有微血管门静脉侵犯(microPVI)患者,以及血清GGT水平在其评估和预后中的作用。